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Abstract
Purpose The aim of this work is to investigate the
characteristics of eyes failing to maintain visual acuity
(VA) receiving variable dosing ranibizumab for neovascular
age-related macular degeneration (nAMD) after three initial
loading doses.
Methods A consecutive series of patients with nAMD,
who, after three loading doses of intravitreal ranibizumab
(0.5 mg each), were re-treated for fluid seen on optical
coherence tomography. After exclusion of eyes with
previous treatment, follow-up less than 12 months, or
missed visits, 99 patients were included in the analysis. The
influence of baseline characteristics, initial VA response,
and central retinal thickness (CRT) fluctuations on the VA
stability from month 3 to month 24 were analyzed using
subgroups and multiple regression analyses.
Results Mean follow-up duration was 21.3 months (range
12–40 months, 32 patients followed-up for ≥24 months).
Secondary loss of VA (loss of five letters or more) after
month 3 was seen in 30 patients (mean VA improvement
from baseline +5.8 letters at month 3, mean loss from
baseline –5.3 letters at month 12 and –9.7 at final visit
up to month 24), while 69 patients maintained vision
(mean gain +8.9 letters at month 3, +10.4 letters at
month 12, and +12.8 letters at final visit up to month 24).
Secondary loss of VA was associated with the presence of
pigment epithelial detachment (PED) at baseline (p 0.01),
but not with baseline fibrosis/atrophy/hemorrhage, CRT
fluctuations, or initial VA response. Chart analysis
revealed additional individual explanations for the sec-
ondary loss of VA, including retinal pigment epithelial
tears, progressive fibrosis, and atrophy.
Conclusions Tissue damage due to degeneration of PED,
retinal pigment epithelial tears, progressive fibrosis, pro-
gressive atrophy, or massive hemorrhage, appears to be
relevant in causing secondary loss of VA despite vascular
endothelial growth factor suppression. PED at baseline may
represent a risk factor.
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Introduction
The inhibition of vascular endothelial growth factor A
(VEGF-A) has proven to be an effective and safe therapy
of neovascular age-related macular degeneration (nAMD)
[1–3]. Ranibizumab, a recombinant, humanized, monoclo-
nal antibody fragment, inhibits all biologically active
forms of VEGF. Intravitreal injections of this molecule
have been investigated in large phase III clinical studies,
which resulted in level I evidence of effectiveness and
safety of this drug. Monthly injections over the course of
2 years were administered to predominantly classic [1, 2],
minimally classic, and occult choroidal neovascularization
(CNV) [3], and, on average, visual acuity (VA) improved
by approximately 1–2 lines, which was highly significant.
This mean gain in VAwas maintained for over 2 years with
monthly injections.
Electronic supplementary material The online version of this article
(doi:10.1007/s00417-011-1734-5) contains supplementary material,
which is available to authorized users.
A. Mariani :A. Deli :A. Ambresin : I. Mantel (*)
Ophthalmology Department, University of Lausanne,
Jules-Gonin Eye Hospital,
15 Av. de France, Case Postale 133,
1000 Lausanne 7, Switzerland
e-mail: i.mantel.widmer@gmx.ch
Graefes Arch Clin Exp Ophthalmol (2011) 249:1635–1642
DOI 10.1007/s00417-011-1734-5
In the PIER study of three consecutive monthly
injections followed by fixed quarterly injections [4, 5],
ranibizumab brought about an initial improvement in mean
VA, followed by a decline of mean VA thereafter, suggesting
that quarterly treatment is inferior to monthly treatment.
However, a subgroup of patients did well and maintained
their initial VA gain [5, 6]. The EXCITE study directly
compared the results of the PIER quarterly regimen with
those of monthly injections [7]. In that study, VA gain
decreased slightly with quarterly dosing, but increased
slightly with monthly doses of ranibizumab.
In clinical practice, most retina specialists employ a
variable dosing regimen based on the results of the
PrONTO study [8]. In the PrONTO study, after an initial
loading dose of three injections of ranibizumab given once
a month, the patients underwent monthly follow-up visits to
determine their need for re-treatment. The most common
reasons for re-treatment were changes seen on optical
coherence tomography (OCT) (recurrent or persistent fluid
or increased central retinal thickness [CRT] of >100 μm)
[8]. Although a small and non-comparative study, results of
the PrONTO study were highly suggestive that mean VA
results comparable to those of the MARINA/ANCHOR
study could be achieved with a variable dosing regimen.
However, the initial VA gain was not entirely maintained.
A meta-analysis has shown that all variable dosing
regimens tend to result in a partial loss of the initial effect,
while fixed monthly dosing results in a slight increase in VA
after month 3 [6].
The aim of the present study was to investigate the
particular characteristics of those eyes with secondary loss
of VA that were treated in a routine clinical practice with a
variable dosing regimen of ranibizumab according to the
principles of the PrONTO study.
Materials and methods
We report an observational study of a consecutive series
of patients with nAMD, who, after the initial 3-monthly
loading doses of intravitreal ranibizumab (0.5 mg each),
were re-treated for fluid seen on optical coherence
tomography at a single center (University Eye Hospital
Jules Gonin, Lausanne, Switzerland) between March
2006 and October 2009. To be included in the analysis,
the eye with nAMD had to be treatment-naive before
initiation of the ranibizumab treatment, and follow-up
duration had to be a minimum of 12 months from
initiation of ranibizumab treatment, with monthly visits.
A total of 99 patients met the criteria and were included
in the study, which was performed in accordance with the
tenets of the Declaration of Helsinki for research
involving human subjects.
Each patient underwent a baseline assessment of best-
corrected VA (BCVA) measured at 4 m with standard
ETDRS charts, and had an ophthalmic examination that
included slit-lamp biomicroscopy, fluorescein angiography
(FA), indocyanine angiography (ICG), and OCT (Stratus
OCT3, Carl Zeiss Meditec, Inc., Oberkochen, Germany)
utilizing six diagonal, slow 6-mm-radial line scans (soft-
ware version 4.0). The central 1-mm subfield with averaged
retinal thickness was used as the CRT. In cases of poor
positioning of the fovea and/or false positioning of the
automatically set marker lines, the investigator chose one
line (with the fovea) and averaged the manual measurement
of the fovea and 0.5 mm from the fovea on both sides.
Initial treatment consisted of three intravitreal injections
of ranibizumab (each injection being 0.5 mg) at monthly
intervals; all injections were performed by a retina
specialist according to the usual technique.
After the three loading doses, each patient underwent a
monthly visit with detailed medical and ocular history, as
well as assessment of BCVA, slit-lamp biomicroscopy,
fundus biomicroscopy, and OCT; FA was performed at the
discretion of the examiner. As a rule, FA was performed in
those cases in which loss of VA could not be explained by
OCT, if there was a large macular hemorrhage, or if
6 months had passed since the last FA.
Intravitreal ranibizumab injection was discontinued after
month 3 (maintenance phase) in eyes that showed an
absence of leakage from the CNV on FA, and a dry macula
(absence of subretinal fluid and cystic maculopathy) on
OCT. Eyes that showed persistent leakage from the CNVon
FA and/or fluid in the macula on OCT and/or increased CRT
of more than 50 μm (compared with smallest previous
measurement) and/or new hemorrhage received an addi-
tional injection. Pigment epithelial detachment (PED) was
not a reason for re-treatment if the overlying retina was dry.
Data collected at each visit included date of the visit,
visual acuity (letters correctly identified on an ETDRS
chart), CRT (OCT Stratus), and treatment decision (ranibi-
zumab injection or no injection). Missing data from
intermediate visits were completed by carrying forward
information from the last observation. Baseline character-
istics included age, gender, eye, angiographic type of CNV
(predominantly classic, minimally classic, occult, or retinal
angiomatous proliferation, as determined by a retina
specialist), lesion size (disc diameters), presence or absence
of PED, and presence or absence of foveal fibrosis/atrophy/
hemorrhage, or hemorrhage covering more than 50% of the
total lesion size.
For data analysis, the statistical program JMP, version
8 (SAS institute Inc., Cary NC, USA), was used. Visual
acuity changes were calculated by letters identified on the
ETDRS chart. Time intervals were calculated in days
(30 days=1 month). At the start of the study, a description
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of the patients was obtained, including the number of
injections, mean VA, and mean CRT findings. As a second
step, the patients were classified into one of two subgroups
depending on their VA curves during the variable dosing
phase (after month 3): Group A consisted of the "main-
tainers", defined as those patients who had the same or
better BCVA or who had experienced a maximum loss of
four letters (less than one line loss on the ETDRS chart)
from month 3 until the latest visit between months 12 and
24. Group B consisted of the "losers", those patients who
experienced a loss of BCVA of five or more letters from
month 3 to the most recent observation. The Wilcoxon/
Kruskal–Wallis test was used to investigate any potential
association with the following parameters: initial VA
response after the 3-monthly loading doses; difference
between the CRT measurements and the thinnest ever
measured CRT value of the same patient, averaged over the
follow-up period (=mean CRT excess); number of injections
per year of follow-up. Fisher's exact test was used for
analyzing potential associations with categorical data
(presence of PED; presence of fibrosis/atrophy/hemorrhage
at baseline).
Because of the somewhat arbitrary threshold between the
two groups, the results were verified by a second approach
using multiple linear regression analysis.
Results
The 99 patients included in this study consisted of 32 men
and 67 women; the mean age of the patients was 78 years
(SD [standard deviation] 8.8 years). Based on baseline FA
and ICG, 22 patients presented with predominantly classic
CNV, five had minimally classic CNV, 58 had occult CNV,
and 14 had retinal angiomatous proliferation. The mean
follow-up for all patients was 21.3 months, which ranged
from 12 to 40 months. Thirty-two patients completed
24 months of follow-up.
Baseline VA ranged from 0.05 (20 letters) to 0.8 (80 letters).
MeanVA onETDRS (Fig. 1a) was 59.2 letters at baseline, but
this rose to 66.6 letters (+7.4 letters) after the first three
injections, then began to drop slightly after month 11 to a
level of 64.8 (+5.6 letters) and to 62.6 (+3.4 letters) at
months 12 and 24, respectively (number of patients=99 and
Fig. 1 Mean visual acuity curve and mean central retinal thickness
curve of patients with age-related macular degeneration treated with
intravitreal ranibizumab. a Mean visual acuity curve (ETDRS letter
score) for all included patients treated with variable dosage intravitreal
ranibizumab for exudative age-related macular degeneration. Error
bars indicate ± 1 standard error of the mean visual acuity change from
baseline. Mean follow-up was 21.3 months (range 12–40 months).
The number of patients who completed 12, 15, 18, 21, and 24 months,
respectively, are indicated (n). The second curve (without error bars)
represents the 61 patients with baseline criteria corresponding to
inclusion criteria of the MARINA and ANCHOR studies. b Mean
central retinal thickness (CRT) curve in micrometers of mean values
for the central subfield on optical coherence tomography measurement
for all included patients treated with variable dosage intravitreal
ranibizumab for exudative age-related macular degeneration. Error
bars indicate ± 1 standard error of the mean central retinal thickness
change from baseline. The second curve (without error bars) are the
61 patients with baseline criteria corresponding to inclusion criteria of
the MARINA and ANCHOR studies
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32, respectively). Visual acuity improved by 15 letters or
more in 24 and 25% of the affected eyes by month 12 and
month 24, respectively. It improved by 0 letters or more in
80% and 70% of the eyes by month 12 and month 24,
respectively. No more than 15 letters were lost in 94 and 89%
of the eyes by month 12 and month 24, respectively.
Visual acuity response (letter change from baseline) at
month 3 was moderately well correlated with the outcome at
12 months (Pearson correlation coefficient r=0.51, p<0.01),
and with the final outcome at up to month 24 (r=0.52,
p<0.01, Fig. 2). The level of baseline VA showed an
insignificant inverse correlation (r=–0.26), and no cor-
relation was found with age (r=–0.12) or with baseline
lesion size (r=–0.09).
The mean number of injections was 6.6 per year of
follow-up (range, 3–12; SD 1.5).
Mean CRT was 306 μm at baseline, but this decreased to
247 μm at month 3 and was maintained thereafter (Fig. 1b).
Individual CRT fluctuations from month 3 to month 24,
however, resulted in individual differences between the
minimal and the maximal value, which ranged between
5 and 238 μm (mean, 58 μm; SD, 39 μm).
Exclusion of the 38 patients whose baseline measure-
ments were outside the criteria of the MARINA and
ANCHOR studies did not significantly change the visual
acuity outcome or mean CRT outcome at any time point
(Fig. 1a and b).
Separating the patients into subgroups A and B,
differentiating between those who "maintained" VA after
month 3 and those who "lost" VA after month 3 (described
in the "Materials and methods" section), revealed that 69
were maintainers and that 30 were losers. Mean follow-up
duration was 21.2 months in the maintainer group, and
22.0 months in the loser group. Mean baseline BCVA was
61 letters (SD 16) in the loser group, and 58 letters (SD 15)
in the maintainer group, which did not represent a
significant difference. The mean BCVA curves of these
two groups did diverge after month 3 but little change was
found after month 12, as shown in Fig. 3a. Most losers
were assigned to their category by month 12 (25 out of 30).
The remaining five eyes changed their category after month
12 with mild VA loss only, while eight other eyes were
transiently in the loser category by month 12, recovering
thereafter. Losers showed a mean VA improvement from
baseline of +5.8 letters (SD 8.5) at month 3, a mean VA loss
from baseline of –5.3 letters (SD 10.2) at month 12, and a
loss of –9.7 (SD 9.9) at the final visit, up to month 24
(mean secondary visual loss was –16.5 letters, SD 12.5).
The 69 patients who maintained their vision showed a mean
gain of +8.9 letters (SD 13.4) at month 3; +10.4 letters (SD
9.5) at month 12 and a gain of +12.8 letters (11.3) at the final
visit (mean secondary visual change was a gain of +4.4 letters
(SD 7.2). In terms of mean CRT, there was a mild statistically
insignificant, difference, with slightly thicker central retinal
subfields seen on OCT in the group of visual acuity losers
(Fig. 3b). However, this curve did not reflect individual
variations in retinal thickness as this disappeared in the
averaged values. VA maintainers showed a mean CRT excess
(after month 3) of 55 μm (SD 32), while VA losers had a
mean excess of 61 μm (SD 48) (statistically insignificant,
Table 1). In all eyes, the fluid had disappeared completely at
the time of their best anatomic response, except for one
patient in the loser group who had persistent subretinal
fluid despite monthly treatment. The number of injec-
tions per year was similar in both groups (secondary
losers: mean 7.8 injections, SD 2.0, in year 1 and 6.5
injections, SD 2.2, in year 2 for those reaching
24 months; maintainers: mean 7.7 injections, SD 2.1, in
year 1 and 6.3 injections, SD 2.3, in year 2 for those
reaching 24 months). Table 1 provides an overview of the
statistical analyses, which showed no significant differ-
ences in initial VA response, mean CRT excess or number
of injections during the maintenance phase.
Baseline characteristics that are known to be associated
with the overall functional outcome of ranibizumab
treatment (age, lesion size, VA at baseline, VA change after
3 months) and did not show any association with the
subgroup of patients who experienced secondary loss of
VA. There were significantly more patients with PED in the
loser group (ten of 30 patients) than in the maintainer group
(eight of 69 patients), with a p value of 0.01 (Fisher's exact
test, Table 1). Of the eight cases of PED in the loser group,
six were found in occult lesions (three fibrovascular, three
serous), and two were present in patients with retinal
Fig. 2 Correlation between visual acuity change after initial three
injections of ranibizumab and final visual acuity change. Bivariate fit
of ETDRS letter score change at last visit, up to month 24, by letter
score change at month 3 (as compared to baseline letter score).
Mathematical equation: (ETDRS M24-M0)=–3.29+1.12*(ETDRS
M3-M0). Pearson correlation coefficient r=0.52, p<0.01
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angiomatous proliferation (two serous). Seven of the eight
patients with PED had been assigned to the secondary loser
category by month 12. However, distribution by angio-
graphic lesion type was similar in both groups (Chi-square
test: predominantly classic CNV, p=0.61; minimally classic
CNV, p=0.28; occult CNV, p=0.16; retinal angiomatous
proliferation, p=0.12). Furthermore, the presence or absence
of central atrophy, fibrosis, or hemorrhage at baseline (which
were inclusion/exclusion criteria of the MARINA and
ANCHOR studies) did not show any association with the
subgroups (eight patients in the maintainer group, five
patients in the loser group).
Multiple linear regression analysis was performed, with the
difference between VA at month 3 and at last visit (or until
month 24) as the continuous parameter. Presence of PED at
baseline was the only factor that remained significant of
poorer outcome (p = 0.02).
A systematic review of the medical records of group B
patients (which consisted of the 30 VA losers) revealed,
for each individual, a viable explanation for the decline
in VA after month 3 (Table 2). Major secondary VA loss
occurred in patients with massive hemorrhage during
follow-up and in those with a retinal pigment epithelial
(RPE) tear (four patients with PED, two patients without
PED at baseline), followed by RPE degeneration in
patients with PED, and foveal atrophy and subfoveal
fibrosis that developed during follow-up. Minor secondary
VA loss occurred in cases with strong recurrence of
exudation, persistent subretinal fluid despite monthly
treatment, and cataract progression.
Discussion
Intravitreal ranibizumab is currently the "gold standard" of
treatment for nAMD, primarily because of its well-
documented efficacy and safety [1–3]. However, the
response of VA varies greatly from one individual to
another. Several factors for functional outcome have been
identified [9–11], but the initial functional response after the
first three injections appears to be particularly predictive of
the long-term result, both in our study and in other reports
Fig. 3 Mean visual acuity curves and mean central retinal thickness
curves in subgroups of secondary visual acuity maintainers and losers.
a Mean visual acuity curve (ETDRS letter score) of the subgroups:
Visual acuity maintainers were those patients treated with ranibizumab
for exudative age-related macular degeneration who maintained best-
corrected visual acuity or lost a maximum of four letters at last
observation (or until month 24) as compared with month 3. The group
of secondary visual acuity losers was defined as those who lost five or
more letters after month 3. The number of patients who completed 12,
15, 18, 21, and 24 months, respectively, are indicated (n). The curves
diverged between months 3 and 12, which corresponded to the early
phase of the variable dosing regimen after the initial loading doses of
ranibizumab. b Mean central retinal thickness curves in microns of
mean values for the central retinal subfield on optical coherence
tomography of the subgroups as described for Fig. 3a. There was a
mild statistically insignificant difference with slightly thicker central
retinal subfields on optical coherence tomography in the group of
visual acuity losers. This curve does not, however, reflect individual
variations in retinal thickness as these disappear in averaged values
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in the literature [11], possibly indicative of the remaining
functional potential of the surviving retinal cells.
The PIER study has shown that less than monthly
treatment (fixed 3-monthly treatments) results in secondary
loss of the initial VA gain in a subgroup of patients ("gain
and not maintain"), in contrast with another subgroup of
patients, which was termed "gain and maintain" [5, 6].
The purpose of the present study was to identify the
subgroup of eyes responsible for the secondary VA decline
of the mean VA curve, and to identify associated character-
istics. A small set of baseline characteristics was examined
(PED, fibrosis, atrophy, hemorrhage), as were some factors
related to the variable dosing regimen (CRT fluctuations,
number of injections).
PED at baseline was associated with statistically
increased risk of secondary VA loss after month 3, an
effect that was independent of the functional response at
month 3. In the large MARINA and ANCHOR trials,
although cases of nAMD with PED could potentially be
included, they were not reported separately. However, a
recent subgroup analysis of patients with moderate to
severe visual loss despite monthly anti-VEGF treatment
found an increased incidence of RPE tears in those with
poor outcome as compared with those with no visual loss
or only mild visual loss, while no difference was found
in the baseline area of serous PED [12]. A retrospective
study of patients with different subfoveal CNV types,
including a group with PED, did not find any difference in
short-term VA results (7 months) [13]. However, many
reports have been published about the risk of RPE tears,
which are present in about 13–17% of nAMD cases with
PED [14–17], but which are seen also in the absence of
PED [18, 19]. Height and extension of the PED have also
been reported to be major risk factors [14, 15]. A tear of
the RPE can cause significant loss of VA despite VEGF
suppression, if the fovea is involved [16]. Our finding that
PED may be associated with secondary visual loss after
month 3 included some cases of RPE tears as well as
progressive RPE degeneration (Table 2).
An association with follow-up parameters such as CRT
fluctuations or number of injections per year could be
expected, because these parameters may reflect insufficient
treatment in the group of secondary losers. The EXCITE
study showed retinal thickness fluctuations that were of
major importance in the "gain and not maintain" (and "no
initial gain") subgroup, suggesting a causal association with
the loss of VA after month 3 (data on file, Novartis Pharma
AG, Basel, Switzerland; presented at the SOE Congress of
the European Society of Ophthalmology, Amsterdam, 2009,
Prünte et al., on behalf of the EXCITE study group). Thus,
recurrent retinal exudation might be associated with slow
loss of BCVA. The variable dosing regimen typically
requires some signs of exudation (fluid on OCT, exudation
on FA or hemorrhage on fundus examination) to reappear
before the patient is re-treated. Thus, during each pre-
treatment period, some damage to the retinal cells may
theoretically occur, which might ultimately translate to
irreversible functional loss of vision. A meta-analysis has
Table 1 Statistical analysis of factors potentially involved in
secondary visual acuity loss (during maintenance phase) in patients
with exudative age-related macular degeneration treated with variable
dosage intravitreal ranibizumab
VA maintainers Secondary VA
losers
p
n=69 n=30
Initial VA change after
3-monthly loading
doses
+8.9 (SD 13.4) +5.8 (SD 8.5) 0.58 n.s.
Mean CRT excess
after month 3
55 μm (SD 32) 61 μm (SD 48) 0.76 n.s.
Number of injections
during years 1 and 2
7.8. (SD 2.0) 7.7 (SD 2.1) 0.82 n.s.
6.5 (SD 2.2) 6.3 (SD 2.3) 0.75 n.s.
Presence of PED 8 (11.6%) 10 (33.3%) 0.01
Angiographic lesion
type at baseline
pc=17 (24.6%) pc=6 (20.0%) 0.61 n.s.
occ=36 (52.2%) occ=11 (36.7%) 0.16 n.s.
mc=3 (4.3%) mc=3 (10.0%) 0.28 n.s.
RAP=13 (18.8%) RAP=10 (33.3%) 0.12 n.s.
Presence of fibrosis/atrophy/
hemorrhage at baseline
8 (11.6%) 5 (16.7%) 0.19 n.s.
n.s. not significant; SD standard deviation; VA visual acuity; CRT
central retinal thickness; PED pigment epithelial detachment; pc
predominantly classic neovascular membrane; occ occult neovascular
membrane; mc minimally classic neovascular membrane; RAP retinal
angiomatous proliferation
Table 2 Individual clinical causes of secondary visual decline of five
letters or more during maintenance phase in patients with exudative
age-related macular degeneration treated with variable dosage intra-
vitreal ranibizumab, by degree of secondary visual loss
Cause n Mean visual acuity
change from month 3
Mean visual acuity
change from
baseline
Massive hemorrhage
occurring during
follow-up
2 –44 –47
Pigment epithelial tear
occurring during
follow-up
6 –26 –23
Pigment epithelial detachment
degeneration
5 –18 –9
Foveal atrophy developing
during follow-up
7 –13 –7
Subfoveal fibrosis developing
during follow-up
7 –10 0
Persistent subfoveal fluid 1 –7 –6
Cataract progression 1 –5 –5
Rapid recurrence with
strong exudation
1 –5 0
Total 30 –16.5 (SD 12.5) –9,7 (SD 9.9)
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shown that all variable dosing regimens tend to result in a
partial loss of the initial effect (similar to our finding), while
fixed monthly dosing results in a slight increase in VA after
month 3 [6]. More recent studies evaluating the variable
dosing with ranibizumab have confirmed the same trend:
functional results at 12 or 24 months are always slightly
lower than at month 3 [20–23] Furthermore, most of these
variable dosing regimens result in lower VA gain at month
12 than would be expected from the MARINA and
ANCHOR studies [21, 24–27]. However, despite the
overall trend of losing some of the gained visual acuity,
some reports have shown relatively good outcomes of the
variable dosing regimen [8, 22, 23].
Recently, Gerding et al. reported a retrospective evalu-
ation that showed a correlation between functional loss of
VA and a preceding increase in CRT. This loss of VA was
only partially reversible, and led, in some patients, to a
permanent functional loss [20]. In a similar way, we chose
to analyze CRT changes. In the present study, we used
averaged values of the individual changes from the thinnest
ever measured CRT, assuming that the smallest value
represented the best anatomical outcome, and that any
higher value was due to liquid (CRT excess). We, however,
did not find an association of secondary visual loss with
individual CRT fluctuations or with the number of
injections. There are several possible explanations for this:
The retinal CRT variations in our sample are relatively
moderate, as we re-treated at thickness increases of 50 μm
(compared to 100 μm in the PrONTO study [8]) or even
before if other signs of fluid were present on OCT. With
such mild fluid fluctuations, a larger sample size might be
needed to show an effect on functional outcome. However,
as a general rule, clinical relevance decreases progressively
with increasing number of subjects needed in order to show
a statistically significant difference. In addition, there are
significant shortcomings of the Stratus OCT in reproducibly
quantifying retinal thickness, and segmentation errors
frequently occur [28]. Patients with reduced VA may have
difficulty with fixation, and central measurement may have
to be manually adjusted, resulting potentially in suboptimal
centralization. The goal of the manual correction used in
our study was to reduce this problem, although it is not
possible to completely correct this error. Well-designed
studies with OCT instruments that more precisely perform
these measurements are needed to better investigate to what
degree CRT fluctuations might cause secondary VA loss in
the variable dosing regimen.
The number of injections was similar in the "loser" and
the "maintainer" groups. In the literature, a trend of lower
efficacy of ranibizumab has been reported in the series with
fewer re-treatments, particularly if less than five injections
per year were given [26, 29]. It has been calculated that 8.4
injections, on average, might be needed to stabilize visual
acuity after month 3 [20]. Our series did not show less
effect with fewer treatments, which might be a consequence
of our very early re-treatment criteria, which results in a
relatively high mean number of re-treatments (an average of
7.8 injections in the first year, and 6.4 injections in the
second year).
The case-by-case chart review of all secondary losers
revealed additional individual explanations for VA loss.
Besides the discussed RPE tears and RPE degeneration
with persistent PED, there were cases of massive subretinal
hemorrhage that caused secondary loss of VA, and mild
secondary VA loss was found to be due to foveal atrophy or
fibrosis that developed during follow-up. Any of these
events could potentially occur, even under complete VEGF
suppression, such as with a monthly regimen of ranibizu-
mab [12]. In the MARINA and ANCHOR studies,
approximately 5–10% of patients had moderate to severe
visual acuity loss (more than 3 lines from baseline)
despite continuous blocking of VEGF [1–3], although
subgroup analysis revealed an association with lesion
characteristics commonly associated with suppressed CNV,
such as pigmentary abnormalities and progression of the
atrophic scar, in the absence of leakage [12]. Thus, we
agree with the conclusion that photoreceptor and RPE
damage may be major factors for long- term loss of VA
despite VEGF suppression, and future improvements in
VA of patients receiving ranibizumab therapy may require
preservation of photoreceptor and RPE cells rather than
targeting the CNV [12].
In conclusion, tissue damage due to PED degeneration,
RPE tears, progressive fibrosis, progressive atrophy, or
massive hemorrhage, appears to be relevant in causing
secondary loss of VA despite VEGF suppression, and
presence or absence of PED at baseline may be an
important risk factor. A variable dosing regimen with
ranibizumab allows overall functional results similar to
those with monthly treatment; at least if the patient is
monitored with monthly visits and if early re-treatment
criteria are in place. However, further studies are warranted
to identify the impact of CRT fluctuations during a variable
dosing regimen with ranibizumab for nAMD.
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